1. Rainsford KD. Anti-inflammatory drugs in the 21st century. Subcell Biochem 2007; 42: 3–27.
2. Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008; 11 (2): 81s–110s.
3. Scarpignato C, Hunt RH. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol. Clin North Am 2010; 39: 433–64.
4. Lanza FL, Chan F, Quigley E et al. Guidelines for Prevention of NSAID-Related Ulcer Complications. Am J Gastroenterol 2009; 104: 728–38.
5. Malfertheiner P, Megraud F, O’Morain C et al. Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646–64.
6. Rostom A, Muir K, Dube C et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007; 5 (7): 818–28, 828e1–5; quiz 768.
7. Chen YF, Jobanputra P, Barton P et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008; 12 (11): 1–278.
8. Ивашкин В.Т., Драпкина О.М. Клиническое значение оксида азота и белков теплового шока. М.: ГЭОТАР-Медиа, 2011; с. 376.
9. Wallace JL, Granger DN. The cellular and molecular basis of gastric mucosal defense. FASEB J 1996; 10: 731–40.
10. Brzozowski T et al. Role of prostaglandins in gastroprotection and gastric adaptation. J Physiol Pharmacol 2005; 56 (Suppl. 5): 33–55.
11. Marcolongo R, Frediani B, Biasi G et al. A Meta-Analysis of the Tolerability of Amtolmetin Guacil, a Novel, Effective Nonsteroidal Anti-Inflammatory Drug, Compared with Established Agents. Clin Drug Invest 1999; 17 (2): 89–96.
12. Tubaro E, Belogi L, Mezzadri CM. The mechanism of action of amtolmetin guacyl, a new gastroprotective nonsteroidal anti-inflammatory drug. Eur J Pharmacol 2000; 387: 233–44.
13. Tubaro E, Belogi L, Mezzadri CM et al. Studies on the gastric tolerability of the new non-steroidal anti-inflammatory drug amtolmetin guacyl. Arzneimittelforschung 1995; 45: 1298.
14. Caruso A, Cutuli VM, De Bernardis E et al. Pharmacological properties and toxicology of MED-15, a prodrug of tolmetin. Drugs Exp Clin Res 1992; 18: 481.
15. Pisano C, Grandi D, Morini G et al. Gastrosparing effect of the new antiinflammatory drug amtolmetin guacyl in the rat: involvement of nitric oxide. Dig Dis Sci 1999; 44 (4): 713–24.
16. Wallace JL. Non-steroidal anti-inflammatory drug gastropathy and cytoprotection: pathogenesis and mechanisms re-examined. Scand J Gastroenterol 1992; 27 (Suppl. 192): 3.
17. Kirkova M, Kesiova M, Konstantinova S et al. In vivo effects of amtolmetin guacyl on lipid peroxidation and antioxidant defence systems in different models of gastrointestinal injury. Autonomic & Autacoid Pharmacol 2007; 27: 63–70.
18. Petazzi I, Corberi G, Bonollo L et al. Clinical study of the therapeutic activity and tolerability of artromed in comparison with piroxicam in rheumatoid arthritic patients. Drugs Exp Clin Res 1990; 16: 31–7.
19. Petazzi I, Corberi G, Bonollo L et al. Evaluation of the time course of the algic-inflammatory symptoms in patients with osteoarthritic afflictions during and after treatment with artromed or diclofenac. Drugs Exp Clin Res 1990; 16: 7–12.
20. Petazzi I, Corberi G, Bonollo L et al. Clinical study of the therapeutic activity and tolerability of artromed in comparison with naproxen in patients with osteoarthritis in different localizations. Drugs Exp Clin Res 1990; 16: 25–30.
21. Jajic Z, Malaise M, Nekam K et al. Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: 9–818.

Т.Л.Лапина

ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России